Patents by Inventor Milos ERAK

Milos ERAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
    Publication number: 20240132556
    Abstract: The invention relates to immunogenic peptides derived from Aquaporin 4 (AQP4) for use in the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD) and to the generation of cytolytic CD4+ T cells or NKT cells against antigen presenting cells that present the wild-type AQP4 epitope sequence.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 25, 2024
    Inventor: Milos ERAK
  • PEPTIDES AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20230340061
    Abstract: The invention relates to immunogenic peptides derived from Myelin Oligodendrocyte Glycoprotein (MOG) for use in the treatment of demyelinating disorders and to the generation of cytolytic CD4+ T cells or NKT cells against antigen presenting cells that present the wild-type MOG epitope sequence.
    Type: Application
    Filed: May 6, 2021
    Publication date: October 26, 2023
    Inventors: Jean-Marie SAINT-REMY, Luc VANDER ELST, Vincent CARLIER, Milos ERAK, Jean VAN RAMPELBERGH, Marcelle VAN MECHELEN, David WALGRAFFE, Geoffrey GLOIRE
  • IMMUNOGENIC PEPTIDES WITH NEW OXIDOREDUCTASE MOTIFS
    Publication number: 20230181638
    Abstract: The invention relates to immunogenic peptides comprising T-cell epitopes and new oxidoreductase motifs with increased activity, and their use in the treatment and/or prevention of type-1 diabetes (T1D), multiple sclerosis (MS), neuromyelitis optica (NMO), or rheumatoid arthritis (RA) in subjects.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 15, 2023
    Inventor: Milos ERAK
  • COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES
    Publication number: 20230172894
    Abstract: The present invention relates to a pharmaceutical preparation (combination or pharmaceutical composition or kit-of-parts) comprising one or more dose units of a fumarate compound and an immunogenic or tolerogenic peptide comprising an oxidoreductase motif and an NKT cell epitope or an MHC class II T cell epitope of an (auto)antigen involved in fumarate related diseases or disorders. The present invention further relates to medical uses of this pharmaceutical preparation.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Inventors: Jean-Marie SAINT-REMY, Luc VANDER ELST, Vincent CARLIER, Milos ERAK, Jean VAN RAMPELBERGH, Marcelle VAN MECHELEN, David WALGRAFFE, Geoffrey GLOIRE, Jean SMAL
  • IMMUNOGENIC PEPTIDES WITH AN OXIDOREDUCTASE MOTIF COMPRISING A MODIFIED CYSTEINE
    Publication number: 20230113747
    Abstract: The invention relates to immunogenic peptides comprising T-cell epitopes and oxidoreductase motifs comprising a modified cysteine, and their use in regulating the immune response in subjects.
    Type: Application
    Filed: May 18, 2020
    Publication date: April 13, 2023
    Inventor: Milos ERAK
  • IMMUNOGENIC PEPTIDES WITH NEW OXIDOREDUCTASE MOTIFS
    Publication number: 20220288179
    Abstract: The invention relates to immunogenic peptides comprising T-cell epitopes and oxidoreductase motifs with increased activity, and their use in regulating the immune response in subjects.
    Type: Application
    Filed: November 12, 2019
    Publication date: September 15, 2022
    Inventor: Milos ERAK
  • IMMUNOGENIC PEPTIDES WITH IMPROVED OXIDOREDUCTASE MOTIFS
    Publication number: 20210401976
    Abstract: The invention relates to immunogenic peptides comprising T-cell epitopes and oxidoreductase motifs with increased activity, and their use in regulating the immune response in subjects.
    Type: Application
    Filed: November 12, 2018
    Publication date: December 30, 2021
    Inventors: Milos ERAK, Luc VANDER ELST